Related references
Note: Only part of the references are listed.EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
Robert Pirker et al.
LANCET ONCOLOGY (2012)
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
Clara Montagut et al.
NATURE MEDICINE (2012)
From SOMAmer-Based Biomarker Discovery to Diagnostic and Clinical Applications: A SOMAmer-Based, Streamlined Multiplex Proteomic Assay
Stephan Kraemer et al.
PLOS ONE (2011)
Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
Alberto Bardelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Expanding the Chemistry of DNA for in Vitro Selection
Jonathan D. Vaught et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2010)
Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins
Darius Ghaderi et al.
NATURE BIOTECHNOLOGY (2010)
Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery
Larry Gold et al.
PLOS ONE (2010)
ErbB receptors and signaling pathways in cancer
Nancy E. Hynes et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Robert Pirker et al.
LANCET (2009)
Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose
Christine H. Chung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
D. L. Wheeler et al.
ONCOGENE (2008)
Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers
Walter P. Carney
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2007)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer
V Gregorc et al.
CLINICAL CANCER RESEARCH (2004)
Pegaptanib for neovascular age-related macular degeneration
ES Gragoudas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Autoantibodies to the epidermal growth factor receptor in systemic sclerosis, lupus, and autoimmune mice
S Planque et al.
FASEB JOURNAL (2003)
Share Paper
